DKSH will provide Cardima with an integrated solution, including regulatory, logistics, marketing, sales, physician training, distribution and after-sales services. Cardima’s electrophysiology products and surgical ablation system have received product registration approval in Thailand.
Additionally, Cardima is partnering with Meds Global, the Thai Ministry of Health, Ramathibodi Hospital and Mahidol University Medical School, to develop a center of excellence in Bangkok, Thailand, for the treatment of atrial fibrillation. Cardima has successfully completed its second phase of cardiothoracic surgeon training in Thailand on the use of the Cardima surgical ablation system in a closed-chest setting.
Robert Cheney, CEO of Cardima, said: “DKSH has a long history and extensive experience marketing medical products in the Asia Pacific region, making it an ideal partner for Cardima in Thailand. We look forward to expanding our partnership with DKSH Healthcare to other major Asian markets as our regulatory strategy advances.”